Top Tweets for #MONOCLONAL
Glad to share this paper @MediPharma_MDPI
"The Role of #Monoclonal #Antibodies as Therapeutics in HPV-Related Head and Neck #Cancers: An Updated #Review"
https://t.co/Xe2KRkmorB
Glad to share this paper @MediPharma_MDPI
"Cost-Effective Method for Full-Length Sequencing of #Monoclonal #Antibodies from Hybridoma #Cells"
https://t.co/xf9mLVd0b9
Glad to share this paper @MediPharma_MDPI
"#Monoclonal #Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence"
https://t.co/LmaN9wnGNG
Glad to share this paper @MediPharma_MDPI
"Advances in Downstream Processing of #Monoclonal Antibodies"
https://t.co/KRBEiVtbep
Glad to share this paper @MediPharma_MDPI
"Impact of #Monoclonal #Antibody Aggregates on Effector Function Characterization"
https://t.co/FMVij3naS1
Glad to share this paper @MediPharma_MDPI
"Treatment of Ebola #Virus Disease: From Serotherapy to the Use of #Monoclonal #Antibodies"
https://t.co/J2Rk5HCwZx
@MSF @BBC @BNOFeed @AfricaCDC @Ebola @WHO @DrTedros @MinofHealthUG @TheUMAofficial @PoliceUg @UgandaMediaCent @WHOUganda @UNICEFUganda @POTUS @TukioDigital @GoCDC @WHOAFRO @ABC @MoHFW_INDIA @narendramodi @cdc @africanews @adoniaayebare @Dr_JeanKaseya @Pandemic_Fund @HelenClarkNZ @CEPIvaccines @Merck @ReutersAfrica @KLM @UNICEFAfrica @DrSJaishankar @Reuters @WHO_Zimbabwe @UNICEFZIMBABWE @KenRoth @Chikwe_I @NHSuk @UKHSA @statnews @emilygraymd_mph @calirunnerdoc @CDCgov @Starlink @NPR 119) American doctor Peter Stafford,who contracted #Bundibugyo #Ebola virus #DRC was successfully treated at Charité-Universitätsmedizin Berlin & safely discharged in good health after 17 days of ICU & quarantine. He received #Monoclonal Antibodies ctd)
Here you have a crystal structure of Secukinumab Fv in complex with human IL-17A (PDB code: 9SFX)
Rendering by Francisco J. Enguita (@fenguita) made with #ProteinImager
#SciArt #molecularart #secukinumab #il17 #antibody #monoclonal #psoriasis #xray
Continuing #ESHMPN2026 with #MeetTheExpert sessions.
Great insight and discussion with @TheElfLab about #CALR, the mechanisms within the cell and the arising new therapies.
#MPN #CARTcell #Monoclonal
#ESHCONFERENCES
A large multicenter cohort study directly compared the isolated and combined impact of detectable serum #monoclonal #gammopathy (MC) and #cryoglobulinemia (CRYO), two #paraproteinemias well recognized in the context of #Sjögren’s disease (SjD) on phenotype and lymphoproliferative risk.
Study design: Multicenter analysis of 1,202 SjD patients from the Italian GRISS registry, stratified by paraproteinemias: MC-alone (4.8%), CRYO-alone (2.7%), MC+CRYO (2.9%), and controls (89.6%).
Key Findings:
◦ Only MC+CRYO group had significantly higher #lymphoma risk (OR 6.30, 95% CI 2.66–14.92; p<0.001). Isolated MC or CRYO did not.
◦ Cryoglobulinemia (alone or combined) linked to #vasculitic features (cutaneous p<0.001, renal p<0.05, PNS p<0.001) and markers (RF p<0.001, low C4 p<0.001).
◦ MC+CRYO additionally associated with lymphoproliferative phenotype: constitutional (p<0.05), glandular (p<0.05), hematological (p<0.001), and lymphadenopathy (p<0.001).
Conclusions:
- Cryoglobulinemia in SjD is primarily associated with vasculitic manifestations and certain laboratory risk markers.
- The coexistence of serum monoclonal gammopathy and cryoglobulinemia defines a separate, more aggressive clinical subset characterized by:
• Broader lymphoproliferative features
• Markedly higher susceptibility to B-cell non-Hodgkin lymphoma
This study highlights the importance of distinguishing isolated versus combined paraproteinemias in SjD for better risk stratification and clinical management.
*Longhino S, Rizzo MT, Manfrè V, et al. Paraproteinemias in Sjögren disease: cryoglobulinemia and serum monoclonal gammopathy identify distinct clinical phenotypes and differential lymphoma susceptibility. Semin Arthritis Rheum. Published online April 19, 2026.
🔗https://t.co/PU4Ex1m4lJ
#Adverse #Events of #Biologics in Severe #Asthma: current evidence on the immediate and long-term safety profile of the available #monoclonal #biological #therapy approved for the treatment of severe asthma.
https://t.co/kg0ASB1F3n
Systematic Review of Kidney #Transplant Outcomes in #Monoclonal #Immunoglobulin #Deposition Disease
#VisualAbstract by @NephroSeeker
https://t.co/XRE3FuIfjf
The #FDA has pledged to reduce #animal #testing for #monoclonal #antibodies.The decision reflects longstanding scientific limitations of animal models in modern #biomedical #research. https://t.co/rO6TNhXCxE
#Monoclonal Gammopathies of #Thrombotic and #Hemorrhagic Significance: Mapping into a classification schem https://t.co/lJKI7Gvxt6
💡Algunas actualizaciones sobre el anticuerpo #monoclonal (mAb) alternativo a la vacuna intramuscular VYD2311
@Invivyd candidato para la prevención de la COVID-19:
La FDA ha otorgado oficialmente la designación de vía rápida al VYD2311: https://t.co/wcgiuH3b2g
• Se ha iniciado el juicio DECLARATION, según lo previsto: https://t.co/lAfr7cBM1c • Aquí está el listado de prueba: https://t.co/h2zsvsU8uo El reclutamiento aún no ha comenzado, pero si usted o alguien que conoce está interesado en inscribirse, se enumeran las 20 ubicaciones que aceptarán inscripciones. Los siguientes estados tienen sitios de inscripción: CA, FL, GA, IL, KS, MD, MA, MI, MN, MO, NJ, NY, PA, SC, TN, TX. 🟣 Actualizaciones anteriores sobre VYD2311: 3 de febrero: Invivyd anuncia datos clínicos positivos de fase 1/2 para VYD2311, un anticuerpo monoclonal diseñado para ser una alternativa superior a la vacunación contra la COVID-19 para la población general: https://t.co/Q0sqPIS4uC . (Invivyd estima una eficacia del 70-90 % contra la COVID-19 sintomática). • 26 de junio: Invivyd anuncia datos clínicos positivos de la fase 1/2 completa para VYD2311, un anticuerpo monoclonal de próxima generación contra la COVID-19 para su posible uso como vacuna no relacionada con la vacuna y para el tratamiento de la infección activa: https://t.co/8UVhgin3P3 • 14 de agosto: Invivyd se alinea con la FDA de EE. UU. en la vía rápida hacia la aprobación completa (BLA) del anticuerpo monoclonal alternativo a la vacuna VYD2311 para proteger a los adultos y adolescentes estadounidenses del COVID-19:
• 6 de octubre: Invivyd anuncia la autorización IND de EE. UU. y la alineación con la FDA de EE. UU. en el programa clínico fundamental para VYD2311, un anticuerpo alternativo a la vacuna para prevenir la COVID:
Some updates on VYD2311, @Invivyd’s intramuscular vaccine-alternative monoclonal antibody (mAb) candidate for the prevention of COVID-19:
• The FDA has officially granted VYD2311 Fast Track designation: https://t.co/70kPGvh1K3
• The DECLARATION trial has been initiated, on schedule: https://t.co/yGuYnNPXXd
• Here is the trial listing: https://t.co/uMFCu8C4SL
Recruitment hasn’t begun just yet, but if you or anyone you know is interested in enrolling, it lists the 20 locations that will be accepting enrollees. The following states have enrollment sites: CA, FL, GA, IL, KS, MD, MA, MI, MN, MO, NJ, NY, PA, SC, TN, TX.
🟣Previous updates on VYD2311:
• February 3rd: Invivyd announces positive phase 1/2 clinical data for VYD2311, a monoclonal antibody designed to be a superior alternative to COVID-19 vaccination for the broad population: https://t.co/AKa6yK6KFH. (Invivyd estimates 70-90% efficacy against symptomatic COVID-19)
• June 26th: Invivyd announces positive full phase 1/2 clinical data for VYD2311, a next generation COVID-19 monoclonal antibody for potential use as a non-vaccine orphanage and for treatment of active infection: https://t.co/hWlD16gqJ4
• August 14th: Invivyd aligns with U.S. FDA on rapid pathway to full approval (BLA) of vaccine alternative monoclonal antibody VYD2311 to protect American adults and adolescents from COVID-19: https://t.co/xu3ZCRPfpr
• October 6th: Invivyd announces US IND clearance and alignment with US FDA on pivotal clinical program for VYD2311, a vaccine-alternative antibody to prevent COVID: https://t.co/DwhmMS6h3U
👏Desde mi propia lucha, celebro este avance. Que la ciencia y la cooperación lleguen a quienes más lo necesitamos. Es un respiro de esperanza. 🫁
#ISSSTE #ASMA #TERAPIA #MONOCLONAL
Esta mañana realizamos una sesión del Consejo Científico del @ISSSTE_mx, en la que firmamos un Convenio entre el ISSSTE, @Birmex y Biocubafarma para trabajar en investigación científica con el propósito de apoyar la producción de vacunas y medicamentos monoclonales.
Safety and tolerability of #astegolimab, an anti-ST2 #monoclonal #antibody: a narrative review. Open Access. https://t.co/fV6tJm9Z4b
#Monoclonal #antibody effects persist for 6 months: a one-time subcutaneous administration of GB-0895 decreased eosinophils, FeNO, IL-13 and IL-5 for 6 months in a phase 1 trial of mild to moderate #asthma. https://t.co/NQmHkw8ueI
@cv_cev @BeccyCooper4Lab We need access to vaccines restored for household members of #Clinically #Vulnerable people too. I DO NOT respond to vaccines & despite promises, @UKLabour government has NOT made #PrEP #monoclonal #antibodies available to protect high risk #immunocompromised. @wesstreeting
@Myeloma_Doc What a great paper by @VincentRK which captures critical updates in #monoclonal #gammopathies!! Thanks for sharing!
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.9M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.6M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.7M followers